Safety Reading Notes

Read safety context beside the research guide.

The CB1 receptor pharmacology source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 40866700

PubMed For Dummies Article

CB1 receptor pharmacology Evidence Review: the long-form source walk-through

Quick read
  • CB1 receptor pharmacology currently has 33 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 40866700
  • The evidence classes most visible in the row language are mechanistic or pharmacological (17), and insufficient (16). PMID 33636308
  • The study-design language most visible in the row language is Narrative or expert review (15), Animal study (9), and Cellular or in vitro study (3). PMID 18537620
  • The repeated topics are CB1 (33), which tells the reader where to start opening PubMed and DOI links. PMID 16596770

Start with the research question

CB1 receptor pharmacology is built from 33 source-backed evidence row(s) and 33 research source(s). The current evidence classes read as mechanistic or pharmacological (17), and insufficient (16), and the study-design language most often reads as Narrative or expert review (15), Animal study (9), and Cellular or in vitro study (3). PMID 40866700

The row-level question is not simply whether CB1 receptor pharmacology is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are CB1 (33). PMID 33636308

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 35489334

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 38101408

Mechanistic evidence 17 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 40044849

Limits and uncertainty 16 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 28527758

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 12505686

Where this page has the most source density

The largest bucket surfaced for this page is CB1: mechanistic or pharmacological. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is CB1: insufficient, which gives readers another way to see what the literature repeatedly circles. PMID 40866700

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 33636308

Bucket chapters: what the literature is circling

CB1: mechanistic or pharmacological

17 research sources 17 rows (809-836) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on CB1: mechanistic or pharmacological. It currently draws from 17 research source(s), so the exact study type matters. PMID 40866700

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 40866700

  • Evidence row 809

    HHC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 40866700

  • Evidence row 836

    Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling m... PMID 40521518

CB1: insufficient

16 research sources 16 rows (806-838) Evidence class: insufficient

This bucket summarizes source-backed rows focused on CB1: insufficient. It currently draws from 16 research source(s), so the exact study type matters. PMID 33636308

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 33636308

  • Evidence row 806

    Cannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signa... PMID 33636308

  • Evidence row 838

    Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 31490743

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (17 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 40866700

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 33636308

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 27245890
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 38830102
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 10469884

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 40866700

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 33636308

Source-reading checklist for CB1 receptor pharmacology

  1. Open the linked PubMed or DOI record. PMID 27879006
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 9974174
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 34500853
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 30333554
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 22343625

Source Notes

CB1 receptor pharmacology source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 806

    Cannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 33636308

    Evidence class: insufficient; Study design: Cellular or in vitro study. Source: Oxa-adamantyl cannabinoids.
  2. Evidence row 807

    Cannabinoids modulates CB1; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 18537620

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
  3. Evidence row 808

    THC modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 16596770

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological actions of cannabinoids.
  4. Evidence row 809

    HHC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 40866700

    Evidence class: mechanistic or pharmacological. Source: Crystal structures of agonist-bound human cannabinoid receptor CB1.
  5. Evidence row 810

    THC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 35489334

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation.
  6. Evidence row 811

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 38101408

    Evidence class: mechanistic or pharmacological. Source: Snapshot of the cannabinoid receptor 1-arrestin complex unravels the biased signaling mechanism.
  7. Evidence row 812

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 40044849

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: A cryptic pocket in CB1 drives peripheral and functional selectivity.
  8. Evidence row 813

    Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 28527758

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.
  9. Evidence row 814

    Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 12505686

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinergic ligands.
  10. Evidence row 815

    Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 27245890

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Assay of CB1 Receptor Binding.
  11. Evidence row 816

    THC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 38830102

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1.
  12. Evidence row 817

    Cannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 10469884

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology of cannabinoid receptor ligands.
  13. Evidence row 818

    Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 27879006

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.
  14. Evidence row 819

    Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 9974174

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The CB1 cannabinoid receptor in the brain.
  15. Evidence row 820

    Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 34500853

    Evidence class: insufficient; Study design: Narrative or expert review. Source: CB1 Cannabinoid Receptor Signaling and Biased Signaling.
  16. Evidence row 821

    Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 30333554

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor.
  17. Evidence row 822

    THC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 22343625

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.
  18. Evidence row 823

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 38675703

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB1 Receptor Negative Allosteric Modulators as a Potential Tool to Reverse Cannabinoid Toxicity.
  19. Evidence row 824

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 16113085

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Allosteric modulation of the cannabinoid CB1 receptor.
  20. Evidence row 825

    THC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 31968549

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.
  21. Evidence row 826

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 28103441

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor.
  22. Evidence row 827

    Endocannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 26408156

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoids and Their Pharmacological Actions.
  23. Evidence row 828

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 29355038

    Evidence class: mechanistic or pharmacological. Source: The future of type 1 cannabinoid receptor allosteric ligands.
  24. Evidence row 829

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 25162172

    Evidence class: mechanistic or pharmacological. Source: Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1).
  25. Evidence row 830

    HHC modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 28678776

    Evidence class: mechanistic or pharmacological. Source: Crystal structures of agonist-bound human cannabinoid receptor CB1.
  26. Evidence row 831

    Cannabinoids modulates CB1; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 29355030

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity.
  27. Evidence row 832

    THC modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 26132518

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Synthetic Cannabinoids.
  28. Evidence row 833

    Endocannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 39828030

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery.
  29. Evidence row 834

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 39695122

    Evidence class: mechanistic or pharmacological. Source: Structural mechanism of CB1R binding to peripheral and biased inverse agonists.
  30. Evidence row 835

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 41559687

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Targeting mechanosensitive cannabinoid receptor 1 with isoflavone prodrugs attenuates atherosclerotic endothelial dysfunction.
  31. Evidence row 836

    Endocannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 40521518

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Synthesis and Pharmacological Characterization of a Novel Cannabinoid Receptor 1 Antagonist.
  32. Evidence row 837

    THC modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 33811300

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.
  33. Evidence row 838

    Cannabinoids modulates CB1; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB1 receptor pharmacology, ligand binding, or signaling mechanisms). PMID 31490743

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Computational Analysis of Dipyrone Metabolite 4-Aminoantipyrine As A Cannabinoid Receptor 1 Agonist.